参考文献/References:
[1] Sung H, Ferlay J, Siegel R L, et al. Global Cancer Statistics 2020:GLOBOCAN Estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249.
[2] Meng L F, Huang J F, Luo P H, et al. The efficacy and safety of immune checkpoint inhibitor plus chemotherapy in patients with advanced non-small-cell lung cancer:a meta-analysis[J]. Invest New Drugs, 2022, 40(4):810-817.
[3] Friedman C F, Proverbs-Singh T A, Postow M A. Treatment of the immune-related adverse effects of immune checkpoint inhibitors:a review[J]. JAMA Oncol, 2016, 2(10):1346-1353.
[4] Naidoo J, Wang X, Woo K M, et al. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy[J]. J Clin Oncol, 2017, 35(7):709-717.
[5] Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer[J]. N Engl J Med, 2018, 379(21):2040-2051.
[6] Yin J, Wu Y, Yang X, et al. Checkpoint inhibitor pneumoni-tis induced by Anti-PD-1/PD-L1 therapy in non-small-cell lung cancer:occurrence and mechanism[J]. Front Immunol, 2022, 13:830631.
[7] Suresh K, Voong K R, Shankar B, et al. Pneumonitis in Non-Small Cell lung cancer patients receiving immune checkpoint immunotherapy:incidence and risk factors[J]. J Thorac Oncol, 2018, 13(12):1930-1939.
[8] Wang D Y, Salem J E, Cohen J V, et al. Fatal toxic effects associated with immune checkpoint inhibitors:a systematic review and meta-analysis[J]. JAMA Oncol, 2018, 4(12):1721-1728.
[9] Kim S, Lim J U. Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer:systematic review of characteristics, incidence, risk factors, and management[J]. J Thorac Dis, 2022, 14(5):1684-1695.
[10] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement[J]. PLoS Med, 2009, 6(7):e1000097.
[11] Stroup D F, Berlin J A, Morton S C, et al. Meta-analysis of observational studies in epidemiology:a proposal for reporting. Meta-analysis of observational studies in Epidemiology(MOOSE)group[J]. JAMA, 2000, 283(15):2008-2012.
[12] Wells G A, Shea B, OConnell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis [EB/OL]. Ottawa, Canada:Ottawa Hospital Research Institute, 2011[2022-10-27]. http://www. ohri. ca/programs/clinical_epidemiology/oxford. asp.
[13] Higgins J P, Thompson S G. Quantifying heterogeneity in a meta-analysis[J]. Stat Med, 2002, 21(11):1539-1558.
[14] Suzuki Y, Karayama M, Uto T, et al. Assessment of Immune-Related Interstitial Lung Disease in Patients With NSCLC Treated with Immune Checkpoint Inhibitors:A Multicenter Prospective Study[J]. J Thorac Oncol, 2020, 15(8):1317-1327.
[15] Chao Y, Zhou J, Hsu S, et al. Risk factors for immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer[J]. Transl Lung Cancer Res, 2022, 11(2):295-306.
[16] Cho J Y, Kim J, Lee J S, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer[J]. Lung Cancer, 2018, 125:150-156.
[17] Atchley W T, Alvarez C, Saxena-Beem S, et al. Immune checkpoint inhibitor-related pneumonitis in lung cancer:real-world incidence, risk factors, and management practices across six health care centers in north carolina [J]. Chest, 2021, 160(2):731-742.
[18] LeClair J N, Merl M Y, Cohenuram M, et al. Real-World incidence of pneumonitis in patients receiving durvalumab[J]. Clin Lung Cancer, 2022, 23(1):34-42.
[19] Reuss J E, Brigham E, Psoter K J, et al. Pretreatment Lung Function and Checkpoint Inhibitor Pneumonitis in NSCLC[J]. JTO Clin Res Rep, 2021, 2(10):100220.
[20] Tiu B C, Zubiri L, Iheke J, et al. Real-world incidence and impact of pneumonitis in patients with lung cancer treated with immune checkpoint inhibitors:a multi-institutional cohort study[J]. J Immunother Cancer, 2022, 10(6):e004670.
[21] Zhang Q, Tang L, Zhou Y, et al. Immune Checkpoint Inhibitor-Associated Pneumonitis in Non-Small Cell Lung Cancer:Current Understanding in Characteristics, Diagnosis, and Management[J]. Front Immunol, 2021, 12:663986.
[22] Sul J, Blumenthal G M, Jiang X P, et al. FDA Approval Summary:pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death ligand 1[J]. Oncologist, 2016, 21(5):643-650.
相似文献/References:
[1]黄郴,徐驯宇.胸腔镜外科领域新进展[J].福建医药杂志,2017,39(4):1.
[2]谢宝松.原发性肺癌规范化诊断——谢宝松教授解读CSCO肺癌指南2018版(视频+典型病例)[J].福建医药杂志,2019,41(06):163.
[3]郑飞,李建成.长链非编码RNA MALAT1对肺癌细胞放疗敏感性的作用[J].福建医药杂志,2021,43(06):125.
ZHENG Fei,LI Jiancheng.Effect of long non-coding RNA MALAT1 on radiosensitivity of lung cancer cells[J].FUJIAN MEDICAL JOURNAL,2021,43(06):125.
[4]刘雪君,佘晖,郑玲容,等.BRD4抑制剂JQ1对慢性阻塞性肺疾病模型小鼠肺功能的影响[J].福建医药杂志,2022,44(01):107.
LIU Xuejun,SHE Hui,ZHENG Lingrong,et al.Effect of BRD4 inhibitor JQ1 on lung function in mice with chronic obstructive pulmonary disease[J].FUJIAN MEDICAL JOURNAL,2022,44(06):107.
[5]雷晓红,王新航,郑珊珊,等.超声评价慢性阻塞性肺疾病患者膈肌形态学与右心功能的相关性[J].福建医药杂志,2024,46(01):30.[doi:10.20148/j.fmj.2014.01.008]